Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 20/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

100%

4 of 4 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 4

3(42.9%)

Phase 2

2(28.6%)

Phase 1

2(28.6%)

7Total

Phase 4(3)

Phase 2(2)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06919796Phase 2Not Yet Recruiting

mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes

Role: lead

NCT06142461Phase 2Withdrawn

Safety and Immunogenicity of HPV Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System

Role: lead

NCT06002503Phase 1Active Not Recruiting

Safety, Reactogenicity and Immunogenicity of a Venezuelan Equine Encephalitis DNA Vaccine Candidate Administered by Jet Injection

Role: lead

NCT03164772Phase 1Completed

Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC

Role: collaborator

NCT01644149Phase 4Completed

Clinical Trial Assessing the Immunologic Response to a Influenza Vaccine Delivered Using an Jet Injection Device or a Needle Syringe

Role: lead

NCT02290691Phase 4Completed

Inactivated Influenza Via Jet Injection

Role: lead

NCT01688921Phase 4Completed

Jet Injection for Influenza

Role: lead

All 7 trials loaded